nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
E-Poster Viewing
|
|
|
|
108 |
S |
p. |
artikel |
2 |
Invited Speakers
|
|
|
|
108 |
S |
p. |
artikel |
3 |
Oral Presentations
|
|
|
|
108 |
S |
p. |
artikel |
4 |
Poster Pitch Presentations
|
|
|
|
108 |
S |
p. |
artikel |
5 |
Presentation name: Hereditary predisposition to MDS
|
Godley, Lucy |
|
|
108 |
S |
p. |
artikel |
6 |
Presentation name: High-Risk MDS
|
Mayer, Margaret |
|
|
108 |
S |
p. |
artikel |
7 |
Presentation Name: How machine learning can contribute to prognostic and predictive models
|
Nazha, Aziz |
|
|
108 |
S |
p. |
artikel |
8 |
Presentation name: Immunotherapy strategies in MDS (vaccines, CAR-T)
|
Gill, Saar |
|
|
108 |
S |
p. |
artikel |
9 |
Presentation name: Inflammatory signaling in the pathogenesis of MDS
|
Sallman, David A. |
|
|
108 |
S |
p. |
artikel |
10 |
Presentation Name: Insights from the MDS transcriptome
|
Boultwood, Jacqueline |
|
|
108 |
S |
p. |
artikel |
11 |
Presentation name: Management of low-risk disease- now and future
|
Platzbecker, Uwe |
|
|
108 |
S |
p. |
artikel |
12 |
Presentation name: MDS progression to AML
|
Murray, Cindy |
|
|
108 |
S |
p. |
artikel |
13 |
Presentation name: Mechanisms and predictors of drug resistance, intolerance to HMAs and clinical management strategies in high-risk MDS
|
Sekeres, Mikkael |
|
|
108 |
S |
p. |
artikel |
14 |
Presentation name: Strategies to reduce relapse and improve survival post allogeneic stem cell transplant
|
Cutler, Corey |
|
|
108 |
S |
p. |
artikel |
15 |
Presentation name: Supportive Care
|
Tinsley-Vance, Sara |
|
|
108 |
S |
p. |
artikel |
16 |
Presentation name: TGFbeta pathway targeting
|
Verma, Amit |
|
|
108 |
S |
p. |
artikel |
17 |
Presentation name: What should be the clinical targets of iron chelation therapy
|
Leitch, Heather |
|
|
108 |
S |
p. |
artikel |
18 |
Presentation name: What we learn from real-world registries
|
de Witte, Prof. Dr. Theo |
|
|
108 |
S |
p. |
artikel |
19 |
The Tito Bastianello Awards
|
|
|
|
108 |
S |
p. |
artikel |
20 |
Topic: AS01-Diagnosis/AS01a-Cytomorphology
|
Ma, J. |
|
|
108 |
S |
p. |
artikel |
21 |
Topic: AS01-Diagnosis/AS01b-Flow cytometry
|
Vicenzetto, C. |
|
|
108 |
S |
p. |
artikel |
22 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression)
|
Garcia, Y. Oliveira |
|
|
108 |
S |
p. |
artikel |
23 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression)
|
Chai, J. |
|
|
108 |
S |
p. |
artikel |
24 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression)
|
Todisco, G. |
|
|
108 |
S |
p. |
artikel |
25 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression)
|
Ferrone, C.K. |
|
|
108 |
S |
p. |
artikel |
26 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression)
|
Eder, L.N. |
|
|
108 |
S |
p. |
artikel |
27 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression)
|
Ferrone, C.K. |
|
|
108 |
S |
p. |
artikel |
28 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression)
|
Huang, H. |
|
|
108 |
S |
p. |
artikel |
29 |
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression)
|
Træden, D. |
|
|
108 |
S |
p. |
artikel |
30 |
Topic: AS02-Epidemiology
|
Brailovski, E. |
|
|
108 |
S |
p. |
artikel |
31 |
Topic: AS02-Epidemiology
|
Dinmohamed, A. |
|
|
108 |
S |
p. |
artikel |
32 |
Topic: AS02-Epidemiology
|
Kuendgen, A. |
|
|
108 |
S |
p. |
artikel |
33 |
Topic: AS02-Epidemiology
|
Al Sabty, I. |
|
|
108 |
S |
p. |
artikel |
34 |
Topic: AS02-Epidemiology
|
Jonasova, A. |
|
|
108 |
S |
p. |
artikel |
35 |
Topic: AS03-Health Economics & Outcome Research/AS03a-Cost of care
|
Kota, V. |
|
|
108 |
S |
p. |
artikel |
36 |
Topic: AS03-Health Economics & Outcome Research/AS03a-Cost of care
|
Zeidan, A.M. |
|
|
108 |
S |
p. |
artikel |
37 |
Topic: AS03-Health Economics & Outcome Research/AS03b-Patient-reported outcomes
|
Bradford, A. |
|
|
108 |
S |
p. |
artikel |
38 |
Topic: AS03-Health Economics & Outcome Research/AS03b-Patient-reported outcomes
|
Haring, Y. |
|
|
108 |
S |
p. |
artikel |
39 |
Topic: AS03-Health Economics & Outcome Research/AS03b-Patient-reported outcomes
|
Dubow, J. |
|
|
108 |
S |
p. |
artikel |
40 |
Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells
|
Saiki, R. |
|
|
108 |
S |
p. |
artikel |
41 |
Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells
|
Yeung, T. |
|
|
108 |
S |
p. |
artikel |
42 |
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution
|
Sahoo, S. |
|
|
108 |
S |
p. |
artikel |
43 |
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution
|
Makishima, H. |
|
|
108 |
S |
p. |
artikel |
44 |
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution
|
Cross, J. |
|
|
108 |
S |
p. |
artikel |
45 |
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution
|
Hartmann, L. |
|
|
108 |
S |
p. |
artikel |
46 |
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution
|
Mohedo, F. Hernández |
|
|
108 |
S |
p. |
artikel |
47 |
Topic: AS04-MDS Biology and Pathogenesis/AS04c-MDS Mouse models (GEMMS, PDX)
|
Fernandez-Orth, J. |
|
|
108 |
S |
p. |
artikel |
48 |
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations
|
Huang, H. |
|
|
108 |
S |
p. |
artikel |
49 |
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations
|
Xu, F. |
|
|
108 |
S |
p. |
artikel |
50 |
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations
|
Zemanova, Z. |
|
|
108 |
S |
p. |
artikel |
51 |
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations
|
Gurnari, C. |
|
|
108 |
S |
p. |
artikel |
52 |
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations
|
Adema, V. |
|
|
108 |
S |
p. |
artikel |
53 |
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations
|
Polprasert, C. |
|
|
108 |
S |
p. |
artikel |
54 |
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations
|
Pu, J. |
|
|
108 |
S |
p. |
artikel |
55 |
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations
|
Zavras, P. |
|
|
108 |
S |
p. |
artikel |
56 |
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations
|
Chiusolo, P. |
|
|
108 |
S |
p. |
artikel |
57 |
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations
|
Huang, H. |
|
|
108 |
S |
p. |
artikel |
58 |
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling
|
Kaisrlikova, M. |
|
|
108 |
S |
p. |
artikel |
59 |
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling
|
Rai, R. |
|
|
108 |
S |
p. |
artikel |
60 |
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling
|
Merkerova, M. |
|
|
108 |
S |
p. |
artikel |
61 |
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling
|
Sousa, T.E. |
|
|
108 |
S |
p. |
artikel |
62 |
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling
|
Gurnari, C. |
|
|
108 |
S |
p. |
artikel |
63 |
Topic: AS04-MDS Biology and Pathogenesis/AS04g-Epigenetic deregulation
|
Poulaki, A. |
|
|
108 |
S |
p. |
artikel |
64 |
Topic: AS04-MDS Biology and Pathogenesis/AS04g-Epigenetic deregulation
|
Brogi, A. |
|
|
108 |
S |
p. |
artikel |
65 |
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation
|
Molero, A. |
|
|
108 |
S |
p. |
artikel |
66 |
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation
|
Molero, A. |
|
|
108 |
S |
p. |
artikel |
67 |
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation
|
Van Ens, D. |
|
|
108 |
S |
p. |
artikel |
68 |
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation
|
Feld, J. |
|
|
108 |
S |
p. |
artikel |
69 |
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation
|
Pagliuca, S. |
|
|
108 |
S |
p. |
artikel |
70 |
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation
|
Calabretto, G. |
|
|
108 |
S |
p. |
artikel |
71 |
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche
|
Wobus, M. |
|
|
108 |
S |
p. |
artikel |
72 |
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche
|
Malka, R. |
|
|
108 |
S |
p. |
artikel |
73 |
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche
|
Solas, T. Jiménez |
|
|
108 |
S |
p. |
artikel |
74 |
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche
|
Kutyna, M. |
|
|
108 |
S |
p. |
artikel |
75 |
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche
|
Jann, J.-C. |
|
|
108 |
S |
p. |
artikel |
76 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment
|
Izquierdo, M. Martín |
|
|
108 |
S |
p. |
artikel |
77 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment
|
Lovatel, V. |
|
|
108 |
S |
p. |
artikel |
78 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment
|
Cedena, M.T. |
|
|
108 |
S |
p. |
artikel |
79 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment
|
Poza, M. |
|
|
108 |
S |
p. |
artikel |
80 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment
|
Blazevic, D. |
|
|
108 |
S |
p. |
artikel |
81 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment
|
Bär, T. |
|
|
108 |
S |
p. |
artikel |
82 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment
|
Smoljanovic, I. Mandac |
|
|
108 |
S |
p. |
artikel |
83 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment
|
Silzle, T. |
|
|
108 |
S |
p. |
artikel |
84 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment
|
Hiwase, D. |
|
|
108 |
S |
p. |
artikel |
85 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment
|
Arenillas, L. |
|
|
108 |
S |
p. |
artikel |
86 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment
|
Roman, D. |
|
|
108 |
S |
p. |
artikel |
87 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment
|
Efraim, M. |
|
|
108 |
S |
p. |
artikel |
88 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment
|
Rabinowitz, R. Book |
|
|
108 |
S |
p. |
artikel |
89 |
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment
|
Trubkina, H. |
|
|
108 |
S |
p. |
artikel |
90 |
Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment
|
Kubasch, A.S. |
|
|
108 |
S |
p. |
artikel |
91 |
Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment
|
Yoshimi, A. |
|
|
108 |
S |
p. |
artikel |
92 |
Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment
|
Cheng, J. |
|
|
108 |
S |
p. |
artikel |
93 |
Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes
|
Bortnick, R. |
|
|
108 |
S |
p. |
artikel |
94 |
Topic: AS08-Treatment/AS08a-Current treatment options - Hypomethylating agents
|
Savona, M. |
|
|
108 |
S |
p. |
artikel |
95 |
Topic: AS08-Treatment/AS08a-Current treatment options - Hypomethylating agents
|
Šimoničová, K. |
|
|
108 |
S |
p. |
artikel |
96 |
Topic: AS08-Treatment/AS08a-Current treatment options - Hypomethylating agents
|
Neokleous, N. |
|
|
108 |
S |
p. |
artikel |
97 |
Topic: AS08-Treatment/AS08b-Current treatment options -Lenalidomide
|
Kravetz, E. |
|
|
108 |
S |
p. |
artikel |
98 |
Topic: AS08-Treatment/AS08e-New developments - Preclinical studies
|
Gharaee, N. |
|
|
108 |
S |
p. |
artikel |
99 |
Topic: AS08-Treatment/AS08e-New developments - Preclinical studies
|
Schmitt, N. |
|
|
108 |
S |
p. |
artikel |
100 |
Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III
|
Cluzeau, T. |
|
|
108 |
S |
p. |
artikel |
101 |
Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III
|
Peterlin, P. |
|
|
108 |
S |
p. |
artikel |
102 |
Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III
|
Zeidan, A.M. |
|
|
108 |
S |
p. |
artikel |
103 |
Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation - Bridging to transplantation
|
Crisà, E. |
|
|
108 |
S |
p. |
artikel |
104 |
Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation
|
Song, Z. |
|
|
108 |
S |
p. |
artikel |
105 |
Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation
|
Garnier, A. |
|
|
108 |
S |
p. |
artikel |
106 |
Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation
|
Duarte, F. |
|
|
108 |
S |
p. |
artikel |
107 |
Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation - Bridging to transplantation
|
Khattab, E. |
|
|
108 |
S |
p. |
artikel |
108 |
Topic: AS08-Treatment/AS08i-Allogeneic hematopoietic cell transplantation -Post-transplantation treatment
|
Choi, E.-J. |
|
|
108 |
S |
p. |
artikel |
109 |
Topic: AS08-Treatment/AS08j-Supportive care - Iron overload
|
Leitch, H. |
|
|
108 |
S |
p. |
artikel |
110 |
Topic: AS08-Treatment/AS08j-Supportive care - Iron overload
|
Zhang, Y. |
|
|
108 |
S |
p. |
artikel |
111 |
Topic: AS08-Treatment/AS08j-Supportive care - Iron overload
|
Rozema, J. |
|
|
108 |
S |
p. |
artikel |
112 |
Topic: AS08-Treatment/AS08k-Supportive care - Transfusion medicine and MDS
|
Mahillo, B. Astibia |
|
|
108 |
S |
p. |
artikel |